Phytomedics gets grant for RA drug development
Phytomedics is a healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources. PMI-001 is a novel, oral, disease-modifying, botanical drug for
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Scynexis, a drug discovery and development company, directs medicinal chemistry, advanced biological screening, bioanalytical and ADMET activities towards Merial’s animal health discovery efforts. Scynexis president and CEO Yves
The grant was awarded under the Foundation’s Therapeutics Development Initiative aimed at supporting preclinical development of Parkinson’s disease therapies that have the potential for fundamentally altering disease course